Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:37:06.516Z.
Consensus retrieved: 2026-10-06T13:16:57.027Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:37:06.516Z.
Quote observation: 2026-10-06T17:35:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 19f1946388931e4ee5326c5171249fc23a65b0c9e42408d49e268755c1a57655
Forward PE Ratio (N/A) = Dated Quote Price ($10.61) / Consensus Forward EPS ($-3.22)
FORWARD PE RATIO
N/A
Kura Oncology, Inc.
Market Cap
$942.07M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Kura Oncology, Inc. (KURA) | $942.07M | N/A |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $940.80M | N/A |
| Savara Inc. (SVRA)vs › | $947.79M | N/A |
| CeriBell, Inc. (CBLL)vs › | $932.78M | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $927.79M | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $965.56M | N/A |
| HealthStream, Inc. (HSTM)vs › | $916.33M | 42.50 |
| Pacira BioSciences, Inc. (PCRX)vs › | $971.18M | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $974.72M | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $977.74M | 35.19 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $10.61, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.22 | $-3.45 – $-2.95 | 10 | n/m |
| 2027-12-31 | $-2.41 | $-3.19 – $-1.54 | 10 | n/m |
| 2028-12-31 | $-1.94 | $-2.95 – $-0.12 | 12 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
